Rémy Cointreau (RMC) H2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
H2 25/26 earnings summary
4 Jun, 2026Executive summary
Launched RC Forward transformation plan to drive growth, efficiency, and resilience amid challenging macroeconomic and geopolitical conditions, with early signs of recovery in key markets and a focus on innovation and market share gains, especially in the US and China.
Leadership transition with Franck Marilly appointed as CEO in June 2025.
Maintained high marketing investment and disciplined financial stewardship, focusing on long-term sustainable value creation.
Strategic focus on stabilizing business, preserving profitability, and improving cash generation.
Financial highlights
Group sales reached €935.3 million (+0.2% organic, -5.0% reported year-over-year).
Current Operating Profit (COP) was €165.4 million, down 11.5% organically and 23.8% reported, with a margin of 17.7%.
Net profit group share was €78.7 million, down 35.1% year-over-year; EPS at €1.51, down 36%.
Free cash flow improved to €53.8 million from €19.2 million last year; FCF conversion rate at 27%.
Net debt/EBITDA ratio increased to 3.22x at March-end, with net financial debt at €690.4 million.
Outlook and guidance
Expect a return to organic sales growth and slight COP margin improvement in 2026/2027, with gradual top-line recovery.
COGS margin expected to remain resilient and improve slightly organically, despite €20 million in tariffs.
Negative FX impact of €15–20 million on sales and €5–8 million on COGS/COP anticipated.
Maintaining net debt/EBITDA below 3.5x is a key priority.
RC Forward aims for €100 million gross value creation by 2028/2029, with medium-term objectives to be announced in November 2026.
Latest events from Rémy Cointreau
- Q4 organic sales up 8.9%, led by Cognac in China, with cautious full-year outlook.RMC
Q4 2026 TU1 May 2026 - Q3 organic sales up 2.8% as U.S. and EMEA gains offset APAC and China weakness.RMC
Q3 2026 TU3 Feb 2026 - Q1 sales dropped 15.6% organically, with gradual recovery and cost controls underway.RMC
Q1 24/25 TU3 Feb 2026 - Sales and profit dropped, but cost savings and recovery with high single-digit growth are targeted.RMC
H2 23/241 Feb 2026 - H1 sales dropped 15.9% organically, triggering revised guidance and a major cost-cutting plan.RMC
H1 24/25 TU18 Jan 2026 - Sales and profit dropped, but margins held up due to aggressive cost controls.RMC
H1 24/2512 Jan 2026 - Q3 sales fell 21.5% organically; full-year decline near 18% with margin guidance held.RMC
Q3 24/25 TU9 Jan 2026 - Sales fell 18% organically; margin guidance held, cost savings and tariff risks remain.RMC
Q4 24/25 TU29 Nov 2025 - Sales and profit declined, but transformation and investment in recovery continue.RMC
H1 25/2627 Nov 2025